ABL1 and cancer: While several resistance mutation hotspots in ABL1 kinase (at gatekeeper, P-loop, αC-helix, and A-loop regions) modulating the binding affinity of different drugs have been well characterised [6], the increased mutation rate in cancers leads to the introduction of variants whose effects on therapeutic efficacy have not been previously studied.